Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PPOX | P50336 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734415 | 1.00 | SCN9A (0.34) | SCN9APOLBGCKLMNAPPOX | |
| SCHEMBL732859 | 0.92 | SCN9A (0.35) | SCN9APOLBGCKPPOXS1PR1 | |
| SCHEMBL732860 | 0.92 | SCN9A (0.35) | SCN9APOLBGCKPPOXS1PR1 | |
| SCHEMBL732341 | 0.91 | PTGDR2 (0.34) | SCN9AKDM4CTBXA2RPTGDRPTGDR2 | |
| SCHEMBL732340 | 0.91 | PTGDR2 (0.34) | SCN9AKDM4CTBXA2RPTGDRPTGDR2 | |
| SCHEMBL733014 | 0.88 | KDM4C (0.34) | SCN9APOLBLMNAS1PR1KDM4C | |
| SCHEMBL733015 | 0.88 | KDM4C (0.34) | SCN9APOLBLMNAS1PR1KDM4C | |
| SCHEMBL733073 | 0.88 | SCN9A (0.36) | SCN9APOLBGCKTBXA2RPTGDR | |
| SCHEMBL733072 | 0.88 | SCN9A (0.36) | SCN9APOLBGCKTBXA2RPTGDR | |
| SCHEMBL733831 | 0.86 | KDM4C (0.36) | SMN1; SMN2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2307383-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| WO-2010006944-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | HRH2, HRH1, HRH4 | SCN9A 2017/4885POLB 3887/4885GCK 1960/4885 |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | SCN9A 2017/4885POLB 3887/4885GCK 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.